Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March: To access the live webcasts of Editas Medicine’s presentations, please visit the ...

Inc. has seen its stock tumble to a 52-week low, touching down at $1.12. With a current market capitalization of just $93 million, the company maintains a strong liquidity position with a current ...

Editas Medicine, Inc. announced that it will release its financial results and business updates for the fourth quarter and full year of 2024 on March 5, 2025, through a press release and SEC ...

Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The ...

Editas Medicine, Inc.’s EDIT share price has surged by 12.20%, which has investors questioning if this is right time to sell.

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have received a consensus rating of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat reports. Two ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be ...

Cost advantage is key for exploration and production firms to achieve a moat. We sell different types of products and services to both investment professionals and individual investors. These ...